N

Novartis

Global pharmaceutical company delivering science-based innovations

Portfolio Account Specialist - Rheumatology

Full-TimePosted on 10/23/2026Deadline 11/13/26
No salary listed
Mid
South Australia, Australia+1 moreMore locations: Victoria, Australia
In Person
Sales & Account ManagementField Sales

About the job

Requirements
  • Experience in healthcare, pharmaceutical sales, or a related commercial role.
  • Strong account management and customer engagement capability.
  • Ability to build trusted relationships with healthcare professionals and key stakeholders.
  • Strong communication, influencing, and negotiation skills.
  • Commercial acumen and ability to identify opportunities for growth.
  • Experience using customer insights and data to support territory and account planning.
Responsibilities
  • Drive competitive sales growth through effective territory and account planning.
  • Identify, prioritise, and engage high-potential healthcare professionals and key stakeholders.
  • Build deep, trusted, and sustained relationships with customers in a compliant and ethical manner.
  • Deliver personalised customer engagement using data, insights, approved content, and multiple engagement channels.
  • Conduct value-based conversations to understand customer challenges, decision drivers, opportunities, and patient needs.
  • Develop and implement territory, account, and customer interaction plans based on customer insights and business priorities.
  • Collaborate with cross-functional teams to deliver solutions that support customers and improve the patient journey.
  • Establish strong working relationships with opinion leaders and key medical influencers at territory level.
  • Share customer insights with internal stakeholders to help inform content, campaigns, and engagement plans.
  • Act with integrity, transparency, and professionalism in all customer and colleague interactions.
  • Ensure all activities are conducted in line with compliance requirements, the Novartis Code of Ethics, and company policies.
  • Report technical complaints, adverse events, and special case scenarios related to Novartis products within required timelines.
Desired Qualifications
  • Established networks within relevant customer groups.
  • Immunology, Dermatology, or specialty care experience.
  • Commercial Excellence.
  • Conflict Management.
  • Cross-Functional Coordination.
  • Customer Insights.
  • Influencing Skills.
  • Key Account Management.
  • Professional Ethics.

About the company

N

Novartis

View
Website

Novartis is a global pharmaceutical company that uses science-based innovations to develop treatments and improve patient outcomes worldwide. Its products are medicines developed through research and development to address various diseases, aiming to reach nearly 1 billion people. The company differentiates itself by large-scale investment in R&D, a global presence with a diverse workforce, and a clear mission to Reimagine Medicine, focusing on meeting the changing needs of patients. Its goal is to improve quality of life and extend life expectancy by delivering meaningful therapies through its research and development efforts.

Company Size

10,001+

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1970

Get referred to Novartis

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Ianalumab won FDA Breakthrough Therapy designation on January 16, 2026.
  • Remibrutinib posted positive Phase III data in April 2026 and September 2026.
  • The October 2, 2026 Abogen deal adds optionality across autoimmune RNA programs.

What critics are saying

  • Entresto generic erosion hits in November 2026 after a September 2026 patent-loss setback.
  • Reuters reported two late-stage failures in September 2026 erased nearly $30 billion.
  • Novartis faces India pricing pressure over ribociclib; Kerala High Court scrutiny continues.

What makes Novartis unique

  • Novartis pairs blockbuster execution with 2026 launches like Rhapsido and Itvisma.
  • Its 2026 autoimmune push spans remibrutinib, ianalumab, and Abogen's ABO2203.
  • CAS collaboration in September 2026 strengthens Novartis's AI-ready reaction data advantage.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 22nd, 2026
Novartis wins EU approval for Cosentyx in polymyalgia rheumatica, a first for IL-17A inhibitors

Novartis has won European Commission approval for Cosentyx to treat polymyalgia rheumatica in adults. It is the first IL-17A inhibitor cleared in Europe specifically for the condition. The approval rests on Phase III trial data supporting use in patients with limited treatment options. The new indication extends Cosentyx's reach in immunology, a priority area for the Swiss drugmaker, which has a market value of CHF241.2 billion. Analysts flag tighter pricing and reimbursement pressure in Europe as a risk for each added indication.

Asianet News
Oct 17th, 2026
Novartis discontinues mid-stage lupus trial in latest pipeline setback.

Novartis discontinues mid-stage lupus trial in latest pipeline setback. Published: Oct 17 2026, 04:05 AM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment in lupus. * Iptacopan is sold under the brand name Fabhalta and is approved by the FDA for Paroxysmal Nocturnal Hemoglobinuria, Primary Immunoglobulin A Nephropathy, and C3 Glomerulopathy. * Novartis has faced multiple clinical setbacks over the past several weeks, including trial failures and development discontinuations. * According to data from Koyfin, 8 of the 23 analysts rate the stock a 'buy' or 'strong buy,' while 13 rate it a 'hold' and only two rate it 'sell.' Shares of Novartis (NVS) closed little changed on Friday after the company decided to discontinue its mid-stage trial of iptacopan in lupus nephritis. According to a federal clinical trials registry update, the company has concluded the study over 'strategic considerations.' It is unclear if the discontinuation was spurred by efficacy or safety concerns. The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment. The company decided to conclude the study after completing the first part, as per the database. Iptacopan is sold under the brand name Fabhalta and is approved by the FDA for Paroxysmal Nocturnal Hemoglobinuria, Primary Immunoglobulin A Nephropathy, and C3 Glomerulopathy. Latest pipeline setback for Novartis. Novartis has faced multiple clinical setbacks over the past several weeks. Last month, the company said that its late-stage trial of Pelacarsen, being developed as a treatment to lower elevated lipoprotein(a) or Lp(a) and reduce the risk of major cardiovascular events, missed its primary goal. The company also said that its late-stage trial of del-desiran in myotonic dystrophy type 1 (DM1) missed its primary endpoint. Besides the late-stage drug failures, the company also discontinued development of VHB937 in mid-September after a mid-stage study missed primary and secondary goals. Prior to that, in August, Novartis paused multiple autoimmune and neurology trials after three fatal cases of immune effector cell-associated hemophagocytic syndrome (IEC-HS) in patients taking its experimental therapy Rap-cel. According to data from Koyfin, 8 of the 23 analysts rate the stock a 'buy' or 'strong buy,' while 13 rate it a 'hold' and only two rate it 'sell.' How did NVS retail traders react? On Stocktwits, retail sentiment around NVS stock stayed within the 'bearish' territory over the past 24 hours, while message volume rose from 'low' to 'normal' levels. NVS stock has gained 9% year-to-date. For updates and corrections, email newsroom[at]stocktwits[dot]com. Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

European Biotechnology
Oct 16th, 2026
Evotec fills CSO vacancy; Sibylla and AL-S Pharma name new CEOs.

Evotec fills CSO vacancy; Sibylla and AL-S Pharma name new CEOs. Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell European Biotechnology about the companies they join. This week: a swift scientific leadership change at Evotec, a broader reshuffle at Sibylla and a new CEO to guide AL-S Pharma toward Phase 3. Evotec: Joanna Holbrook takes over as CSO. Holbrook will join the management board on Nov. 1, succeeding Cord Dohrmann, who stepped down Sept. 30 by mutual agreement after 16 years in the role. Holbrook joins from Novo Nordisk, where she led research in cardiovascular, renal and hepatic disease as well as in vitro discovery platforms. At Evotec, she will oversee scientific strategy across its discovery and development services and technology platforms. Go deeper. Sibylla Biotech: Four executive changes ahead of the clinic. The Italian biotech named Usman Azam CEO and Gianluca Fuggetta CFO. Azam led CAR-T developer Tmunity Therapeutics for more than five years and previously headed Novartis' cell and gene therapies unit. Sibylla cofounder and former CEO Lidia Pieri becomes COO, while Elena Ardini moves up to CSO. The team will advance Sibylla's lead Cyclin D1 protein degrader toward a first human study. Go deeper. AL-S Pharma: Harry Welten becomes CEO. He succeeds Michael Salzmann as the Swiss biotech prepares a confirmatory Phase 3 trial of AP-101, an antibody targeting misfolded SOD1 in amyotrophic lateral sclerosis. Welten says financing and partnerships will be priorities. The company now aims to start Phase 3 in 2027, a shift from its March target of late 2026. Its earlier Phase 2 study met a primary endpoint focused on safety. Go deeper. Integra Therapeutics: Simon Dew joins to build partnerships. Dew becomes chief business officer at the Barcelona biotech, joining from Macomics after earlier business development roles at several cell and gene therapy companies. Integra wants him to find partners for FiCAT, its preclinical gene-writing platform for cell and gene therapies. The company closed a €10.7 million financing in 2025, intended to validate CAR-T applications and prepare the technology for transfer to pharma partners. Go deeper. TETRAPHARM: Rolf Sass Sørensen succeeds a cofounder. Sørensen became CEO on Oct. 6, replacing Martin Rose. Rose and fellow cofounder Jesper Breum are leaving operational roles to pursue new biotech ventures but remain shareholders. Sørensen, a former Bavarian Nordic investor relations executive, takes over a business combining preclinical drug programs with contract development and manufacturing services. Go deeper. | (C) european biotechnology | Joachim Eeckhout 16 October 2026 |

The Pharma Letter
Oct 13th, 2026
Sibylla names ex-Novartis cell and gene therapy head Usman Azam CEO.

Sibylla names ex-Novartis cell and gene therapy head Usman Azam CEO. 13 October 2026 Italy's Sibylla Biotech, an oncology firm developing small-molecule protein degraders that interfere with protein folding, has appointed Usman Azam as chief executive and Gianluca Fuggetta as chief financial officer, as it prepares to take its lead program into first-in-human studies. Lidia Pieri, a co-founder and Sibylla's previous chief executive, becomes chief operating officer, and Elena Ardini is promoted from vice president of research and development to chief scientific officer. The company said the changes reflect progress in validating its folding-interference technology and its plan to move its lead program, a degrader targeting cyclin D1, into the clinic. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 8 May 2025 12 October 2026 14 March 2024 Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 13 October 2026 Company spotlight. An RNA therapeutics platform company enabling discovery and development of modular and programmable RNA medicines. More features in biotechnology. 13 October 2026

PR Newswire
Oct 8th, 2026
INVESTOR ALERT: Pomerantz law Firm investigates claims on behalf of investors of Novartis AG - NVS.

INVESTOR ALERT: Pomerantz law Firm investigates claims on behalf of investors of Novartis AG - NVS. Oct 08, 2026, 10:00 ET NEW YORK, Oct. 8, 2026 /PRNewswire/ - Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Novartis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On September 8, 2026, Novartis issued a press release "announc[ing] that the global Phase III HARBOR study evaluating del-desiran in people living with myotonic dystrophy type 1 (DM1) did not demonstrate statistically significant improvement versus placebo on the primary endpoint of video hand opening time (vHOT), a novel measure of hand myotonia." On this news, Novartis's American Depositary Share ("ADS") price fell $22.29 per ADS, or 13.93%, to close at $137.70 per ADS on September 8, 2026. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. SOURCE Pomerantz LLP